Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases

芬戈莫德 医学 耐受性 药理学 多发性硬化 不利影响 肿瘤科 免疫学
作者
Daniele D’Ambrosio,Mark S. Freedman,Joerg C. Prinz
出处
期刊:Therapeutic Advances in Chronic Disease [SAGE]
卷期号:7 (1): 18-33 被引量:87
标识
DOI:10.1177/2040622315617354
摘要

The first oral treatment for relapsing multiple sclerosis, the nonselective sphingosine-1-phosphate receptor (S1PR) modulator fingolimod, led to identification of a pivotal role of sphingosine-1-phosphate and one of its five known receptors, S1P1R, in regulation of lymphocyte trafficking in multiple sclerosis. Modulation of S1P3R, initially thought to cause some of fingolimod's side effects, prompted the search for novel compounds with high selectivity for S1P1R. Ponesimod is an orally active, selective S1P1R modulator that causes dose-dependent sequestration of lymphocytes in lymphoid organs. In contrast to the long half-life/slow elimination of fingolimod, ponesimod is eliminated within 1 week of discontinuation and its pharmacological effects are rapidly reversible. Clinical data in multiple sclerosis have shown a dose-dependent therapeutic effect of ponesimod and defined 20 mg as a daily dose with desired efficacy, and acceptable safety and tolerability. Phase II clinical data have also shown therapeutic efficacy of ponesimod in psoriasis. These findings have increased our understanding of psoriasis pathogenesis and suggest clinical utility of S1P1R modulation for treatment of various immune-mediated disorders. A gradual dose titration regimen was found to minimize the cardiac effects associated with initiation of ponesimod treatment. Selectivity for S1P1R, rapid onset and reversibility of pharmacological effects, and an optimized titration regimen differentiate ponesimod from fingolimod, and may lead to better safety and tolerability. Ponesimod is currently in phase III clinical development to assess efficacy and safety in relapsing multiple sclerosis. A phase II study is also ongoing to investigate the potential utility of ponesimod in chronic graft versus host disease.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
鹏鹏完成签到 ,获得积分10
刚刚
kakax完成签到,获得积分10
刚刚
七七完成签到,获得积分10
1秒前
zzz发布了新的文献求助10
2秒前
Moonflower完成签到,获得积分10
2秒前
凌晨四点完成签到,获得积分10
2秒前
zhaoyuqing发布了新的文献求助10
2秒前
4秒前
5秒前
平常的半凡完成签到 ,获得积分10
11秒前
hhhblabla应助曾珍采纳,获得50
11秒前
深情安青应助wund采纳,获得10
15秒前
Moonflower发布了新的文献求助10
15秒前
15秒前
16秒前
ding应助科研通管家采纳,获得10
16秒前
烟花应助科研通管家采纳,获得10
16秒前
XIE应助科研通管家采纳,获得20
16秒前
情怀应助科研通管家采纳,获得10
16秒前
深情安青应助科研通管家采纳,获得30
16秒前
无花果应助科研通管家采纳,获得10
16秒前
丨叶修应助科研通管家采纳,获得10
16秒前
大模型应助科研通管家采纳,获得10
17秒前
17秒前
17秒前
helloclare完成签到,获得积分10
17秒前
写歌养猫盖城堡完成签到,获得积分10
17秒前
不安的浩宇完成签到,获得积分10
19秒前
19秒前
21秒前
22秒前
锐哥发布了新的文献求助10
22秒前
Owen应助阮楷瑞采纳,获得10
22秒前
lalala应助啊汪~采纳,获得10
22秒前
乐乐应助锐哥采纳,获得10
25秒前
丘比特应助胡可采纳,获得10
26秒前
wund发布了新的文献求助10
27秒前
29秒前
英姑应助浩二采纳,获得10
33秒前
阮楷瑞发布了新的文献求助10
34秒前
高分求助中
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger Heßler, Claudia, Rud 1000
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 1000
Natural History of Mantodea 螳螂的自然史 1000
A Photographic Guide to Mantis of China 常见螳螂野外识别手册 800
Barge Mooring (Oilfield Seamanship Series Volume 6) 600
ANSYS Workbench基础教程与实例详解 500
Spatial Political Economy: Uneven Development and the Production of Nature in Chile 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 内科学 物理 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 免疫学 细胞生物学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 3325288
求助须知:如何正确求助?哪些是违规求助? 2955988
关于积分的说明 8578548
捐赠科研通 2633885
什么是DOI,文献DOI怎么找? 1441560
科研通“疑难数据库(出版商)”最低求助积分说明 667885
邀请新用户注册赠送积分活动 654600